Glucagon has a positive inotropic effect in normal hearts but is ineffective in animals with chronic cardiac failure. To assess directly the influence of glucagon on the human myocardium, we measured contractility and activation of adenyl cyclase, the enzyme thought to mediate the inotropic action of glucagon, in left ventricular papillary muscles obtained from 12 patients at mitral valve replacement. On the basis of preoperative ventricular end-diastolic pressures and cardiac output (independent of papillary muscle data) patients were classified in three groups: normal, cardiac failure, and condition indeterminate. Concentration-response curves showed that glucagon caused a mean rise of 11% in peak papillary muscle tension and a rise of 12% in peak rate of tension development in the normal patients; myocardial adenyl cyclase activity from each normal patient rose after glucagon (average, 84%). In the papillary muscles of the patients with cardiac failure, glucagon did not augment either tension or adenyl cyclase activity. In contrast, contractility and adenyl cyclase activity increased after norepinephrine in both normal patients and those with cardiac failure. The indeterminate group had two patients whose papillary muscles responded to glucagon and two whose papillary muscles did not respond. Thus, direct study of human papillary muscles shows that chronic cardiac failure is uniformly associated with complete loss of the normal enhancement of contractility and associated activation of adenyl cyclase after glucagon. This perhaps explains the inefficacy of this drug in treating patients with chronic cardiac failure. 
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Additional Indexing Words: Catheterization data
Rheumatic heart disease T HE POSITIVE inotropic influence of glucagon has been well documented in normal experimental animals1-3 and in patients with only mild impairment of cardiac function.4-6 Administration of similar or even
From the Cardiology Branch, National Heart and Lung Institute, Bethesda, Maryland 20014. EFFECTS OF CHRONIC HEART FAILURE ON GLUCAGON glucagon.12 However, neither mechanical nor biochemical responsiveness to norepinephrine was impaired in the failing myocardium. These findings suggested that a specific, failure-induced insensitivity to glucagon might explain the inconsistent effects of glucagon in patients with chronic congestive heart failure. To test this hypothesis more directly, we evaluated alterations in contractility and in adenyl cyclase activity after glucagon and after norepinephrine in myocardial preparations obtained at operation from severe valvular disease. These four individuals will subsequently be termed "normal." Five patients had a subnormal cardiac index and elevated ventricular end-diastolic pressures (group III). These individuals will be designated the "congestive failure" group. No distinction was made between the two patients with gross elevation of right ventricular end-diastolic pressure but normal or borderline normal left ventricular end-diastolic pressure and the three with biventricular elevation of end-diastolic pressure. This grouping of patients was subsequently justified by the homogenous performance of the papillary muscles taken from these five individuals. T-he remaining four patients (group II) had nolmal ventricular end-diastolic pressures but a cardiac index below 2.5 liters/min/m2. The low cardiac index in these patients might reflect excessive diuresis or obstruction to ventricular inflow rather than myocardial dysfunction. Thus it was not possible to determine with certainty whether myocardial function in these four patients was normal or abnormal by simply relating ventricular enddiastolic pressure and cardiac index. These patients consequently formed a group designated "indeterminate."
Mitral valve replacement was performed in 12 of the 13 patients. The one exception (M.W.) had a mitral commissurotomy; a Circulation, Volume XLIV, October 1971 A small but consistent concentration-related augmentation of peak tension and peak dT/dt was observed in each muscle from the normal group when incubated with glucagon ( fig. 1  and table 4) . However, no increase or an actual decrease in peak tension and peak dT/dt occurred when muscles from the congestive failure group were exposed to glucagon. Maximum percentage change in tension for all muscles is shown in figure 2 . After glucagon (left panel) the mean increase of 11% in muscles from the normal group is significantly different from the mean decrease of 8% exhibited by muscles from patients with congestive failure. The response of muscles from the indeterminate group was intermediate: two muscles showed an increase in peak tension and two did not. Changes in time to peak tension were small and inconsistent for all three groups.
Response to Norepinephrine Unlike glucagon, norepinephrine caused a concentration-dependent rise in peak tension and in peak dT/dt and a fall in time to peak tension ( fig. 2 Glucagon-induced change in adenyl cyclase activity (picomoles of cyclic 3',5'-AMP/mg protein/3 min) on the ordinate is plotted against maximum percentage change in peak active tension after glucagon on the abscissa. Values presented are for the individual patients in the normal and CHF groups with the greatest and the least change in cyclase activity. Values for all three patients are given for the indeterminate group. Rise in papillary muscle active tension after glucagon was uniformly associated with a marked increase in myocardial adenyl cyclase activity after glucagon. Conversely, failure to increase tension aftet glucagon was associated with little or no rise in adenyl cyclase activity. The correlation coefficient for these data is 0.71. patient (C.R.). Lack of appreciable increase in adenyl cyclase activity with glucagon was also evident in preparations made from papillary muscles of both ventricles in the one patient tested (C.R.).
Discussion
When patients undergoing mitral valve replacement were divided into normal and congestive failure categories in accordance with simple hemodynamic criteria, a striking dichotomy of glucagon responsiveness became apparent. Papillary muscles from patients with normal cardiac indices as well as normal left epinephrine increased mean adenyl cyclase activity in preparations from all three groups. The differences between the group means after norepinephrine were not statistically significant. figure 4 , mechanical and biochemical responsiveness to glucagon correlated closely (r = 0.71) for each individual, regardless of grouping. A significant rise in adenyl cyclase activity was always associated with an increase in peak tension and, conversely, was never associated with failure to increase tension. This close relationship between mechanical and biochemical responsiveness suggests that the inability of glucagon to augment contractility in patients with chronic failure is due to inability of glucagon to activate adenyl cyclase, the enzyme thought to mediate the inotropic effects of glucagon.14 The fact that adenyl cyclase activity uniformly increased with norepinephrine, even in those preparations which were unresponsive to glucagon, implies that the unresponsiveness was not due to a defect in the enzyme itself. Rather, our data suggest an impairment in the binding of glucagon to its cellular receptor, or to an "uncoupling" of the receptor to adenyl cyclase. Analogous studies in cats resulted in similar conclusions.12 The consistent responsiveness to norepinephrine also tends to exclude the possibility that lack of response to glucagon was the nonspecific result of fibrous replacement of myocardium in diseased papillary muscles. It also tends to exclude impaired diffusion of glucagon into papillary muscles as a cause of lack of mechanical response.
Because of their relatively large size, human papillary muscles might be expected to provide somewhat less satisfactory preparations than papillary muscles from cats or other small animals. Though tailored to reduce their size, these muscles, when placed in the myograph, may have a central core of tissue whose contractile performance is limited by oxygen diffusion. The tailoring process also tends to result in wide variability in muscle cross-sectional area. Despite these potential limitations, all of the muscles studied showed an increased contractility in response to paired stimulation or norepinephrine. Thus, each muscle was capable of responding to an inotropic stimulus regardless of the clinical and hemodynamic classification of the patient from whom it was derived. It would seem reasonable, therefore, to assume that the selective failure of response to glucagon exhibited by muscles from individuals with congestive failure reflected a true alteration in myocardial sensitivity to glucagon rather than an artifactual change. This conclusion is substantiated by similar results obtained with the smaller untailored, more uniform papillary muscles of the cat12 and also by the parallel results observed in our adenyl cyclase studies.
Our data offer an explanation for the disappointing results obtained when glucagon is used in the treatment of patients with chronic heart failure: cardiac failure appears to alter the myocardium selectively so that glucagon no longer augments contractility. This alteration does not appear to affect catecholamine responsiveness."8 Clinical studies of the inotropic efficacy of glucagon, however, do not reveal the same dichotomy of "responders" and "nonresponders" seen in the present study. For example, certain patients in the detailed study of Williams and coworkers7 showed evidence of improvement in cardiac function after glucagon despite low cardiac index and elevated end-diastolic pressures. Thus, our relatively clear-cut results would superficially appear to differ from results obtained in the intact human heart. This discrepancy may be related to the difficulties inherent in evaluating the effects of glucagon on myocardial contractility in the catheterization laboratory. Aside from the problems of assessing the action of a relatively slow-acting agent in ill patients who frequently have arrhythmias or some degree of circulatory instability, glucagon often induces nausea and vomiting when administered in therapeutic doses. These effects might initiate autonomic Circulation, Volume XLIV, October 1971 changes and thereby reflexly alter contractility. Glucagon also has been shown to release catecholamines from the adrenal medullal9; this property is the basis of a provocative test for pheochromocytoma.20 Although adrenal release of catecholamines is of little importance in mediating the inotropic influence of glucagon in normal animals,' it may be sufficient to influence contractile function when the direct positive inotropic properties of glucagon are absent. Thus there are several possible reasons to explain why inotropic response to glucagon would be more variable when assessed in the catheterization laboratory than when examined using the papillary muscle.
